Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Fred Wagshul

Clinical Nurse Specialist, Family Health Dayton, OH Medical Doctor

NPI 1336137595 CMS profile 1169917

8371 Yankee St, Dayton, OH 45458

Open in the dashboard

General payments

$5,351

303 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Fred Wagshul of Dayton, OH is reported in the CMS Open Payments database as having received $5,351 across 303 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Clinical Nurse Specialist, Family Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,245 64
2024 General $752 43
2023 General $724 36
2022 General $331 18
2021 General $714 41
2020 General $691 41
2019 General $894 60

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Fred Wagshul
  • Clinical Nurse Specialist, Family Health median
  • Middle half of Clinical Nurse Specialist, Family Health
  • National median

In program year 2025, general payments to Fred Wagshul were reported at $1,245. Among 164 Clinical Nurse Specialist, Family Health profiles paid that year, the median was $216 and the middle half received between $57 and $492.

Show as a table
Year Fred Wagshul Clinical Nurse Specialist, Family Health median Middle half National median
2019 $894 — — $163
2020 $691 — — $114
2021 $714 $151 $46–$400 $132
2022 $331 $153 $37–$527 $149
2023 $724 $139 $50–$451 $160
2024 $752 $150 $46–$571 $164
2025 $1,245 $216 $57–$492 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Grifols USA, LLC $1,586 93 payments
  2. AstraZeneca Pharmaceuticals LP $943 42 payments
  3. GlaxoSmithKline, LLC. $712 52 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $401 20 payments
  5. Mylan Specialty L.P. $352 24 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $221 14 payments
  7. Genzyme Corporation $141 6 payments
  8. Novo Nordisk Inc $131 7 payments
  9. Mallinckrodt Hospital Products Inc. $127 5 payments
  10. Pulmonx Corporation $74 2 payments
  11. Other $663 38 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,351 303 payments
Products named General payments · program years 2019–2025
  1. Prolastin-C Liquid $1,586 93 payments
  2. TRELEGY ELLIPTA $427 32 payments
  3. YUPELRI $395 26 payments
  4. GLASSIA $381 20 payments
  5. SYMBICORT $304 8 payments
  6. AIRSUPRA $217 12 payments
  7. SPIRIVA RESPIMAT $168 11 payments
  8. TEZSPIRE $161 8 payments
  9. DUPIXENT $141 6 payments
  10. FASENRA $138 2 payments
  11. Other $2,002 99 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

400

Median for Pulmonary Disease: 936

Drug cost

$55,139

Median for Pulmonary Disease: $487,987

Branded share of claims

35.5%

Median for Pulmonary Disease: 69.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 36 $38,671
Symbicort Budesonide/Formoterol Fumarate Brand 18 $5,227
Wixela Inhub Fluticasone Propion/Salmeterol Brand 11 $2,747
Azithromycin Generic 79 $1,849
Novolog Mix 70-30 Flexpen Insulin Aspart Prot/Insuln Asp Brand 12 $1,590
Albuterol Sulfate Hfa Albuterol Sulfate Brand 36 $1,466
Clarithromycin Generic 14 $1,302
Doxycycline Hyclate Generic 37 $1,029
Montelukast Sodium Generic 24 $428
Methylprednisolone Generic 33 $200

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,233 Part D prescribers listed as Pulmonary Disease; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 23 billing codes

Paid by Medicare

$97,413

Of which drugs: $94

Medicare patients

314

Average age 73

Services billed

2,418

198 women, 116 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 68%
COPD 68%
Arthritis 51%
Ischemic heart disease 29%
Diabetes 25%
Heart failure 20%
Depression 20%
Osteoporosis 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, ceftriaxone sodium, per 250 mg J0696 Office 42 275 $87
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 45 81 $7

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Prolastin-C Liquid
  • Grifols USA, LLC $200
$200 — —
YUPELRI
  • Mylan Specialty L.P. $178
$178 — —
Wegovy
  • Novo Nordisk Inc $55
$55 — —
GLASSIA
  • Takeda Pharmaceuticals U.S.A., Inc. $53
$53 — —
DUPIXENT
  • GENZYME CORPORATION $51
$51 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

303 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Nurse Specialist, Family Health in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record